TEL-AVIV, Israel and RALEIGH, NC, July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC (the "Agreement"). As a result of the Agreement, RedHill received approximately $9.9 million in cash and gained full control over an additional $0.74 million currently held in a restricted account, lead ...

文章核心观点 - 公司与Cosmo Technologies Ltd.达成共识,自愿终止在美国的Aemcolo独家许可协议 [1][2] - 终止后,Aemcolo的所有权利将全部归还给Cosmo [2] - 公司将立即停止Aemcolo的商业化活动 [2] 公司概况 - 公司是一家专注于胃肠道和传染病的专科生物制药公司 [3] - 公司主要产品包括用于治疗幽门螺杆菌感染的Talicia®和用于治疗旅行者腹泻的Aemcolo® [3] - 公司还有多个处于临床后期开发阶段的重点项目,包括opaganib、RHB-107和RHB-102等 [3] 终止协议原因 - 公司与Cosmo团队进行了谨慎的共同考虑后做出了停止Aemcolo商业化的决定 [3] - 公司首席商务官对Cosmo团队过去几年的合作表示感谢 [3]

New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response[1]. Provides protection for opaganib's potential use in combination with a range of approved and in-development (ICIs) across a growing range of indications[2] through 2040 ICIs have become a cornerstone in cancer treatment, having been hailed as a major breakthrough by oncologists, with the global ICI market expected to exceed $100 bi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 2023 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2023 TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, Page 2023, IN U.S. DOLLARS: Condensed consolidated interim statements of comprehensive income (loss) 3 Condensed consolidated interim statements of financial position 4 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File No.:001-3577 3 REDHILL BIOPHARMA LTD. (Translation of registrant’s name into English) 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Fo ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q1 2022 Results Conference Call June 23, 2022 8:30 AM ET Company Participants Debbie Bechor - Business Development & Communications Manager Dror Ben-Asher - Chief Executive Officer Rick Scruggs - President and Chief Commercial Officer Guy Goldberg - Chief Business Officer Gilead Raday - Chief Operating Officer Micha Ben-Chorin - Chief Financial Officer Adi Frish - Chief Corporate and Business Development Officer Rob Jackson - Senior Vice President of Marketing Conference ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Alexandra Okmian Sanderovich - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Guy Goldberg - Chief Business Officer Gilead Raday - Chief Operating Officer Rob Jackson - Senior VP, Sales & Marketing Micha Ben Chorin - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Hoang - SMBC Boobalan Pachaiyap ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q3 2021 Earnings Conference Call November 30, 2021 8:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and IR Manager Dror Ben-Asher - CEO Guy Goldberg - Chief Business Officer Gilead Raday - COO Rob Jackson - SVP, Sales and Marketing Micha Ben-Chorin - CFO Bob Gilkin - SVP, Market Access and Trade Relations Conference Call Participants Brandon Folkes - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright David Hoang - SMBC Robert Hazlett ...